Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

High-dose Melphalan (MEL) is the standard conditioning regimen used for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). Generic MEL is routinely used in various transplant centers across the world including ours due to its reduced cost and ease of availability. We compared the pharmacokinetics (PK) and the clinical efficacy of generic MEL with that of the innovator formulation in MM patients undergoing ASCT.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 3, 2019 Category: Hematology Authors: Aswin Anand Pai, Anup J. Devasia, John Carl Panetta, Sathya Mani, Raveen Stephen Stallon Illangeswaran, Ezhilpavai Mohanan, Balaji Balakrishnan, Kavitha M. L, Uday Kulkarni, Fouzia NA, Anu Korula, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George, Tags: Original Study Source Type: research